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between 1980  and  2012
Dear Editor,
We  read with great interest the article entitled “Trends in
mortality of adult patients diagnosed with myeloid leukemia
from 1994 to 2011 in southeastern Brazil” by Callera et al.
published in the Revista Brasileira de Hematologia e Hemoterapia
(2015;37(1):7–11),1 and we would like to make some comments.
The subject of the article is very important for clinical
oncology and cancer surveillance as it presents a time series
analysis showing a declining trend in mortality from myeloid
leukemia in one area of the richest region of Brazil. It is under-
stood that this decline is a result of the improving quality of
access to health services with early diagnosis of the disease
and clinical management. However, Brazil is the size of a conti-
nental and, therefore, we  believe it is important to observe the
trend of mortality due to myeloid leukemia in other regions of
Brazil and the country as a whole.
In 2014, the Brazilian National Cancer Institute estimated
the incidence of leukemia in Brazil to be around 5050 and
4320 new cases for men  and women, respectively. Exclud-
ing non-melanoma skin tumors, leukemia is the ﬁfth most
common cancer in men  in the Northern Region of the
country (3.57/100,000) and in the Northeastern Region, it
is the eighth most common (4.15/100,000). However, in the
South (8.13/100,000), Southeast (5.42/100,000) and Midwest
(4.14/100,000), it is ranked the tenth most common can-
cer. For women, it is the seventh most common cancer in
the North (2.81/100,000), the eighth most common in the
South (6.30/100,000) and in the Northeast (3.40/100,000), it is
ranked the tenth most common malignancy. In the Southeast
(4.50/100,000) and Midwest (3.41/100,000), it is the eleventh
most frequent.2
This inconsistency has been observed worldwide. GLOBO-
CAN estimates the global prevalence of leukemia to be
4.7/100,000 inhabitants. The same report shows, however, that
there are differences in the rates when comparing medium
(3.8/100,000) and under (2.5/100,000) developed countries.
With regard to mortality, the global estimate is 3.4/100,000inhabitants, 3.2/100,000 for medium and 2.4/100,000 for under
development countries.3
By using a methodology4 similar to Callera et al.,1 we
identiﬁed important differences in different Brazilian regions.
Myeloid leukemia mortality rates between 1980 and 2012 are
different when stratiﬁed by gender. The rates in men  are
consistently higher [in 1987 in Brazil (24.65%), in 1988 in the
Midwest (42.71%), in 1982 in the Northeast (40.78%), in 1985 in
the North (71.79%) and, more  recently, in 2003 in the Southeast
(26.13%) and the South (34.67%)], which may point to impor-
tant differences between the genders. In addition, the rates are
consistently higher in the Southeast and South, regardless of
gender, which shows regional differences in the impact of the
disease (Figure 1).
Regarding the trend, there is a difference related to gen-
der and region. For males, there was a signiﬁcant increase
in the incidence rates in Brazil between 1980 and 2005. After
2005, there was a statistically non-signiﬁcant drop in the
rates. In the Midwest, North and South, there were signiﬁcant
and linear increases for the entire period. For the Northeast,
there were two periods of signiﬁcant increases (at different
degrees): 1980–1997 and 1997–2007. Since then, there has been
no signiﬁcant decrease. The Southeast has shown a signiﬁ-
cant reduction in rates from 2001, after a period of signiﬁcant
increases between 1980 and 2001.
For women, Brazil has seen a statistically signiﬁcant
decline since 2003, although the rate increased between 1980
and 1996, and from 1996 to 2003, by different extents. The
Northern region and Midwest have had signiﬁcant linear
increases in rates for the whole period, similar to males.
The Northeast has shown a cyclic ﬂuctuation, with a non-
signiﬁcant increase between 1980 and 1996, a signiﬁcant
increase between 1996 and 2004, and a non-signiﬁcant decline
between 2004 and 2012. The Southeast and South showed sig-
niﬁcant increases between 1980 and 2004, and 1980 and 2005.
After that, a non-signiﬁcant decrease was seen (Table 1).
Today, the prognosis for patients with leukemia is better
than in previous years. Primary and secondary prevention
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trategies have provided increased survival rates for patients
uffering from myeloid leukemia.5 Both incidence and mor-
ality rates are difﬁcult to interpret because leukemia is often
iagnosed incidentally or while evaluating other conditions.
herefore, differences in medical care may be a substantial
ias in respect to incidence data. Moreover, due to differences
n access to treatment, there are considerable variations in
urvival rates worldwide, which may explain the differences
n the rates in speciﬁc regions of Brazil.
There are also huge regional differences related to sec-
ndary prevention strategies, which are better in the South
nd Southeast, and worse in the North and Northeast.
onetheless, some particularities ought to be consideredoid leukemia adjusted for age by gender.
when discussing risk factors. For example, there are places
in the North where the soil has a natural source of radiation
and Brazil has the highest rate of pesticide use in the world.
Finally, drops in mortality rates are associated with the
improvement of the use of antibiotics, such as voriconazole,
caspofungin and piperacillin/tazobactam, which have low tox-
icity (less renal and hepatic lesions).
In summary, we believe that a time trend analysis is a rele-
vant tool to analyze health status. The decrease in leukemia in
the Paraíba Valley, São Paulo, clearly shows the impact that the
organization of services (for early diagnosis, appropriate treat-
ment and reducing exposure to environmental agents) has on
disease control. Considering the diversity of existing trends
174  rev bras hematol hemoter.
Table 1 – Annual percentage change in the leukemia
mortality rate adjusted for age by gender.
Region Period APC 95% CI p-Value
Range
Men
Brazil 1980–2005 1.12 0.90 1.34 <0.001
2005–2012 −1.42 −2.86 0.05 0.058
Midwest 1980–2012 1.86 0.95 2.77 <0.001
Northeast 1980–1997 1.89 1.06 2.71 <0.001
1997–2007 5.12 2.95 7.39 <0.001
2007–2012 −1.81 −6.76 3.43 0.477
North 1980–2012 3.41 2.35 4.48 <0.001
Southeast 1980–2001 0.16 0.24 0.94 0.002
2001–2012 −1.41 −2.31 −0.49 0.004
South 1980–2012 0.68 0.29 1.13 0.002
Women
Brazil 1980–1996 0.58 0.12 1.04 0.015
1996–2003 2.69 0.64 4.78 0.012
2003–2012 −1.66 −2.72 −0.58  0.004
Midwest 1980–2012 1.47 0.82 2.11 <0.001
Northeast 1980–1996 0.65 −0.45 1.77 0.236
1996–2004 6.43 2.41 10.61 0.003
2004–2012 −0.13 −3.22 3.07 0.936
North 1980–2012 2.41 1.25 3.59 <0.001
Southeast 1980–2004 0.65 0.34 0.97 <0.001
2004–2012 −2.88 −4.48 −1.25 0.001
South 1980–2005 1.47 1.07 1.88 <0.001
2005–2008 −6.32 −23.63 14.90 0.516
2008–2012 4.33 −2.19 11.29 0.189
r
1
2
3
4
5
1516-8484/© 2016 Associac¸ão Brasileira de Hematologia,
Hemoterapia e Terapia Celular. Published by Elsevier EditoraAPC: annual percent change; 95% CI: 95% conﬁdence interval.
in Brazil, it is important to identify areas where the trend is
still increasing in order to adapt public health strategies from
where the trend is decreasing to achieve a positive result in
the country as a whole.Conﬂicts  of  interest
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